Amicus Therapeutics, Inc. $FOLD Shares Sold by Granite Investment Partners LLC

Granite Investment Partners LLC cut its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 2.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,118,696 shares of the biopharmaceutical company’s stock after selling 42,506 shares during the period. Amicus Therapeutics makes up approximately 0.9% of Granite Investment Partners LLC’s investment portfolio, making the stock its 24th biggest position. Granite Investment Partners LLC owned approximately 0.69% of Amicus Therapeutics worth $16,695,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Osaic Holdings Inc. boosted its stake in Amicus Therapeutics by 450.1% during the 2nd quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 3,358 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Amicus Therapeutics by 472.6% in the second quarter. EverSource Wealth Advisors LLC now owns 4,455 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 3,677 shares during the period. Strs Ohio bought a new position in Amicus Therapeutics during the first quarter valued at about $30,000. ANTIPODES PARTNERS Ltd acquired a new position in Amicus Therapeutics during the third quarter worth about $31,000. Finally, Versant Capital Management Inc raised its position in Amicus Therapeutics by 499.1% in the third quarter. Versant Capital Management Inc now owns 5,266 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 4,387 shares in the last quarter.

Amicus Therapeutics Stock Down 0.1%

Shares of NASDAQ:FOLD opened at $14.34 on Monday. The firm has a 50 day simple moving average of $14.02 and a 200 day simple moving average of $10.45. Amicus Therapeutics, Inc. has a 52 week low of $5.51 and a 52 week high of $14.38. The company has a debt-to-equity ratio of 1.70, a quick ratio of 2.09 and a current ratio of 2.99. The company has a market cap of $4.50 billion, a PE ratio of -179.25 and a beta of 0.38.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Wednesday, February 25th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.13 by ($0.03). The firm had revenue of $185.21 million for the quarter, compared to analyst estimates of $185.00 million. Amicus Therapeutics had a negative net margin of 4.27% and a positive return on equity of 4.47%. Amicus Therapeutics’s revenue for the quarter was up 23.7% compared to the same quarter last year. During the same period last year, the firm earned $0.09 earnings per share. As a group, research analysts expect that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current year.

Insider Buying and Selling

In other Amicus Therapeutics news, insider Ellen Rosenberg sold 23,621 shares of the firm’s stock in a transaction dated Wednesday, November 26th. The stock was sold at an average price of $10.00, for a total transaction of $236,210.00. Following the completion of the sale, the insider directly owned 507,710 shares in the company, valued at approximately $5,077,100. This trade represents a 4.45% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider David Michael Clark sold 25,642 shares of Amicus Therapeutics stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $14.17, for a total value of $363,347.14. Following the transaction, the insider directly owned 245,690 shares in the company, valued at approximately $3,481,427.30. This trade represents a 9.45% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 278,419 shares of company stock valued at $3,307,172. Corporate insiders own 2.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Amicus Therapeutics in a research report on Monday, December 29th. Zacks Research cut shares of Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, January 26th. The Goldman Sachs Group lifted their price target on shares of Amicus Therapeutics from $9.00 to $11.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 5th. Citigroup reaffirmed a “neutral” rating and issued a $14.50 price target (down previously from $17.00) on shares of Amicus Therapeutics in a report on Monday, December 22nd. Finally, Cantor Fitzgerald lowered Amicus Therapeutics from an “overweight” rating to a “hold” rating and reduced their price objective for the stock from $21.00 to $14.50 in a research note on Friday, December 19th. Three investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $15.39.

Amicus Therapeutics Profile

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.